Gentium (GENT) is an Italian biotech company that provides unique treatment options to patients faced with rare diseases with high unmet medical needs. Gentium is an excellent growth play on its investigational drug Defibrotide. However, the stock appears reasonably valued after rising ~200% from its 52-week low at $6.96. I believe that the stock could correct ~30% from its recent high at $22.40. This would provide investors an excellent buying opportunity with a favorable risk-reward ratio.
Gentium is a multi-product biopharmaceutical company that develops drugs primarily sourced from DNAs. Defibrotide, Gentium's lead product candidate, has been designed for treatment and prevention of veno-occlusive disease ("VOD"). Defibrotide is derived from porcine mucosal DNA. Phase III clinical trial of Defibrotide
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|